Dupixent (Dupilumab) · Cost by Insurance Type · Savings Programs · Medicare Part D
Dupixent’s list price exceeds $4,000 per month — but most patients pay far less, and many pay nothing at all. What you actually owe depends almost entirely on whether you have commercial insurance, Medicare Part D, Medicaid, or no coverage at all. This guide breaks it down by situation so you can find your number and the specific programs that apply to you.
⚕️ Medical & Financial Information Only: This guide covers Dupixent pricing and assistance programs only. It does not constitute medical advice and does not replace guidance from your prescribing physician or pharmacist. Always discuss treatment decisions, costs, and assistance program eligibility with your healthcare team.
💡 The One Paragraph That Changes Everything
Dupixent is a biologic medication made by Regeneron and Sanofi. It works by blocking two specific immune signals — interleukin-4 and interleukin-13 — that drive the chronic inflammation behind conditions including moderate-to-severe eczema (atopic dermatitis), asthma, COPD, nasal polyps, prurigo nodularis, eosinophilic esophagitis, chronic hives, and bullous pemphigoid. Because it’s a biologic manufactured from living cells, it cannot be made as a generic tablet. The list price for a one-month supply (two prefilled injections) is approximately $4,193 as of early 2026. But here is what that number actually means for most patients: roughly 68% of commercially insured patients pay $0–$100 per month through the manufacturer’s copay card. About 79% of Medicare Part D patients pay $0–$100 per month once their plan’s cost-sharing structure and the 2026 Part D cap kick in. Medicaid patients in most states pay $4–$9 per month. Uninsured patients who meet income eligibility can receive the medication at no cost through the Patient Assistance Program. The brutal sticker price is not what most people actually pay — but figuring out your specific path requires knowing which category you fall into.
💰 Dupixent Monthly Cost — By Insurance Type
The table below reflects current real-world out-of-pocket costs by coverage type. “List price” is what you would pay with no assistance of any kind. Most patients have access to at least one program that dramatically reduces this.
| Coverage Type | Typical Monthly Cost | Key Program Available |
|---|---|---|
| No insurance (list price) | $4,000–$5,500Cash price at specialty pharmacies — varies by location and dose | Patient Assistance Program (PAP) if income-eligible; discount cards reduce cash price modestly |
| Commercial / Employer Insurance Copay Card Available | $0–$100/mo~68% of patients land here · Copay card covers up to $13,000/year | DUPIXENT MyWay® Copay Card — eligible patients may pay $0 per fill |
| Medicare Part D | $0–$100/mo~79% pay in this range · $2,100 annual OOP cap for 2026 | $2,100 annual cap · Extra Help/LIS for lower-income enrollees · Medicare Prescription Payment Plan |
| Medicaid | $4–$9/moCoverage and copay vary by state · Prior auth usually required | State Medicaid program — check your specific state’s formulary and copay structure |
| Uninsured / Income Eligible | $0/mo (if approved)Free medication through Patient Assistance Program · ~400% FPL income threshold | DUPIXENT MyWay® PAP — call 1-844-387-4936 · Prescriber must co-sign enrollment |
| ACA Marketplace Plans | Varies widelyUsually covered; prior auth often required; copay card typically applies | DUPIXENT MyWay® Copay Card applies to most marketplace plans · Check formulary first |
⚠️ The Copay Card Cannot Be Used With Medicare or Medicaid
This is one of the most common points of confusion. The DUPIXENT MyWay® Copay Card is not valid for Medicare, Medicaid, VA, TRICARE, or any other federal or state government insurance program. Federal anti-kickback rules prohibit manufacturers from offsetting cost-sharing for government-insured patients. If you have Medicare or Medicaid, your cost reduction path runs through the Patient Assistance Program (PAP), Extra Help / Low-Income Subsidy, or state pharmaceutical assistance programs — not the copay card.
📋 Most-Asked Questions — Answered Plainly
These are the specific questions people search when trying to navigate Dupixent costs — including why insurance denies it, how to get it for free, what Medicare covers, and whether a cheaper version exists.
-
1
How much is a one-month supply of Dupixent? List price: ~$4,193 per carton (2 injections) · Cash price at pharmacy: $3,993–$5,449 depending on dose and location · Most insured patients pay $0–$100/month through assistance programsA one-month supply of Dupixent consists of two prefilled syringes or autoinjector pens for most dosing schedules. The manufacturer’s wholesale list price is approximately $4,193 per carton as of early 2026. By the time that price reaches a retail specialty pharmacy, it can climb to $4,500–$5,500 depending on pharmacy markup and location. GoodRx and other discount programs can reduce the cash price to roughly $3,800–$4,500, though even this discounted price is out of reach for most people without some form of assistance. The critical distinction is between the list price — what you’d pay with zero assistance — and what patients actually pay through the combination of insurance, copay programs, and patient assistance. For most patients with any form of coverage, the real out-of-pocket number is dramatically lower than the headline figure. Dupixent is dispensed exclusively through specialty pharmacies, not standard retail pharmacies. Your prescriber’s office or the DUPIXENT MyWay® program can help connect you to a specialty pharmacy in your area and network.
-
2
How do I get Dupixent for free? Uninsured or low-income: DUPIXENT MyWay® PAP — free medication if household income is around 400% FPL ($63,840/year for a single person) · Commercial insurance: Copay card covers cost up to $13,000/year, making most fills $0 · Medicare patients: PAP requires first applying for Extra HelpThere are two main paths to $0 Dupixent. The first is for commercially insured patients: the DUPIXENT MyWay® Copay Card covers most or all of your copay and coinsurance up to a program maximum of $13,000 per year. For patients whose commercial plan covers Dupixent, this effectively makes the drug free or very close to it — about 68% of commercially insured patients reach the $0 or near-$0 tier. The second path is for uninsured patients or those who cannot afford the drug: the DUPIXENT MyWay® Patient Assistance Program provides free medication to eligible patients. Income thresholds are evaluated on a case-by-case basis, with reported eligibility around 400% of the Federal Poverty Level — approximately $63,840 for a single-person household. Your prescriber must co-sign the enrollment form. To start either process, call DUPIXENT MyWay® at 1-844-387-4936 (option 1), Monday through Friday, 8 a.m. to 9 p.m. ET. Medicare patients who want to use the PAP first need to apply for Extra Help through Social Security (even if they expect to be denied) — the denial letter is required documentation for the PAP to provide assistance.
-
3
How much does Dupixent cost with Medicare Part D? Most Medicare Part D patients: $0–$100 per month (79% land here) · 2026 annual out-of-pocket cap: $2,100 · Once you hit $2,100 for the year, covered drugs cost you $0 for the rest of the year · Extra Help available for low-income enrollees (income ≤150% FPL)Medicare Part D covers Dupixent under approximately 99% of Part D plans, though prior authorization is required. The 2026 redesign of Part D dramatically changed the math for expensive specialty drugs like Dupixent. The annual out-of-pocket cap is $2,100 in 2026 — meaning once your total cost-sharing for all covered Part D drugs reaches $2,100, your plan picks up 100% of covered medication costs for the rest of the calendar year. At list price, most patients reach this cap during the first or second fill of the year, then pay nothing for the remaining 10 or 11 months. This makes Dupixent’s effective annual cost under Medicare Part D closer to $2,100 maximum for most patients, not $4,000 per month multiplied by 12. For patients who struggle to pay even the initial out-of-pocket costs before reaching the cap, two options exist. First, the Medicare Prescription Payment Plan (voluntary, free to join) spreads the $2,100 annual maximum into equal monthly installments with no interest or fees. Second, Extra Help / Low-Income Subsidy reduces copays to roughly $3–$9 per prescription for patients whose income is at or below 150% of the federal poverty level — apply through Social Security Administration at 1-800-772-1213 or ssa.gov.
-
4
Why is Dupixent so expensive? Biologic manufacturing costs · 9 FDA-approved indications creating broad demand · No biosimilar competition (patent protection through mid-2030s) · U.S. drug pricing structure allows manufacturers to set list prices without negotiation · R&D costs for clinical trials cited by manufacturerDupixent’s price reflects the intersection of how biologics are made, how U.S. drug pricing works, and how market exclusivity functions for pharmaceuticals. Biologics like Dupixent are manufactured using living cells in highly controlled bioreactor systems — a fundamentally more complex and expensive process than synthesizing a chemical compound. The drug does not have a biosimilar competitor in the U.S.: patent protections extend through the mid-2030s, meaning no competing product can legally enter the market at lower cost for years. In other countries — Canada, the UK, Germany, France — government negotiation mechanisms cap what manufacturers can charge for the same drug. In the U.S., prior to limited Medicare negotiation authority under recent legislation, no such mechanism existed at scale. The result is that the same dose of dupilumab costs a fraction of the U.S. price in most other wealthy nations. Within the U.S. system, the list price also functions partly as a negotiating anchor — insurers and pharmacy benefit managers negotiate rebates from the manufacturer, often undisclosed, that bring the actual cost paid by plans below the list price. Patients without insurance see the list price; insured patients see their plan’s negotiated cost-sharing structure instead.
-
5
Is there a cheaper version of Dupixent? No — no generic, no biosimilar, and no cheaper equivalent exist in the U.S. as of mid-2026 · Patent protection runs through the mid-2030s · No FDA-approved biosimilar is in the pipeline for near-term approval · The DUPIXENT MyWay® programs are the primary cost-reduction toolsThere is no generic version, no biosimilar, and no cheaper equivalent to Dupixent available at any U.S. pharmacy. This is one of the most commonly asked questions, and the answer is straightforwardly no — not now, and not soon. Dupixent is a biologic, meaning it is made from living cells rather than synthesized chemically. When a biologic’s patent expires, what becomes available is a biosimilar — a closely related product, not an identical generic — and that still requires FDA approval and substantial clinical trials. Dupixent’s patent protection through the mid-2030s means biosimilar manufacturers cannot even legally begin the approval process for the U.S. market in any commercially meaningful way. For patients who cannot afford the drug and don’t qualify for the manufacturer’s assistance programs, the practical alternatives are: discussing with your doctor whether other FDA-approved therapies for your condition might be covered at lower cost, requesting samples from your prescriber’s office to bridge a coverage gap, or applying to the Patient Advocate Foundation’s Co-Pay Relief Program (copayrelief.org) or NeedyMeds (needymeds.org) for additional financial assistance sources.
-
6
Why won’t insurance cover Dupixent — and what can I do about it? Most denials are for prior authorization failure or step therapy — not permanent rejections · Common fix: your doctor submits documentation of failed prior treatments · Peer-to-peer review between your doctor and the insurance medical director succeeds frequently · External review (free to patients) overturns about 50% of denials in many statesAn insurance denial for Dupixent is usually not a final answer — it’s the beginning of a process. Almost all commercial insurers and Medicare Part D plans require prior authorization (PA) because Dupixent costs approximately $48,000–$65,000 per year at list price. The PA process asks your doctor to document that you meet specific clinical criteria. For atopic dermatitis (eczema), this typically means documented failure of at least two topical therapies such as corticosteroids and calcineurin inhibitors. For asthma, it means documented eosinophilic phenotype with blood counts above 150 cells per microliter or oral steroid dependence. Denials most often happen when the PA submission is missing required documentation, not because the drug is categorically excluded. Your prescriber’s office should request a peer-to-peer review — a direct call between your doctor and the insurance plan’s medical director. These succeed at high rates when documentation is thorough. If the internal appeal is denied, most states offer an Independent Medical Review (IMR) or external review process that is free to patients and results in a binding decision. These overturn approximately 50% of pharmacy benefit denials in states with robust external review laws. Contact your state insurance commissioner’s office if you’re unsure of the process. Your state’s insurance complaint process — not the insurer’s customer service — is where external review requests are filed.
-
7
Is Dupixent available at Walmart or through a discount pharmacy? No — Dupixent requires a specialty pharmacy · Standard retail pharmacies including Walmart, CVS front-end, and Walgreens do not stock it · It must be dispensed through a specialty pharmacy authorized to handle biologics · Your insurer may require a specific specialty pharmacy (OptumRx, Walgreens Specialty, CVS Specialty, etc.)Dupixent cannot be picked up at a standard retail pharmacy counter. Because it’s a biologic requiring temperature-controlled handling and specialized dispensing protocols, it is exclusively available through specialty pharmacies. Walmart Pharmacy is not a specialty pharmacy for Dupixent. CVS and Walgreens operate separate specialty pharmacy divisions (CVS Specialty and Walgreens Specialty Pharmacy) that are distinct from their retail locations — you would need to fill through those divisions specifically. Your insurance plan may mandate a specific specialty pharmacy. For example, UnitedHealthcare commonly requires dispensing through OptumRx Specialty Pharmacy; Humana often uses CenterWell Specialty Pharmacy. Using an out-of-network specialty pharmacy can result in a coverage denial or significantly higher out-of-pocket costs even if you have a valid prior authorization in hand. When your PA is approved, confirm with your insurer which specialty pharmacies are in-network before placing your first order. If you’re uninsured or using the PAP program, DUPIXENT MyWay® can connect you directly to an appropriate specialty pharmacy and handle the shipping and delivery process.
-
8
What conditions does Dupixent treat — and does the condition affect cost? FDA-approved for 9 conditions including eczema, asthma, COPD, nasal polyps, prurigo nodularis, eosinophilic esophagitis, chronic hives, bullous pemphigoid, and eosinophilic asthma · Off-label use may not be covered · The dose schedule (every 2 weeks vs. every 4 weeks) affects monthly cost · Condition affects prior authorization criteria, not the drug price itselfDupixent’s list price per injection is the same regardless of which condition it’s treating. What does differ by condition is the dosing schedule — some conditions require every-two-week injections while others use every-four-week dosing — which affects how many pens are dispensed per month and therefore the total monthly cost. For FDA-approved indications, insurance coverage pathways are available, though the specific clinical criteria for prior authorization vary by condition. For off-label use (conditions not on the FDA-approved label), coverage is substantially more difficult to obtain and often requires compelling medical necessity documentation. The insurance prior authorization criteria are also condition-specific: eczema patients typically need documented failure of topical therapies; asthma patients need documented eosinophilic blood counts and controlled inhaled therapy; nasal polyp patients need documented inadequate response to nasal corticosteroids. If your prescriber writes the prescription for the condition that most closely matches the clinical criteria your plan uses, the approval process goes more smoothly. Talk to your doctor about how the PA is being framed, particularly if you have multiple qualifying conditions.
🔍 What to Do Based on Your Specific Situation
I have commercial insurance but my copay is still hundreds of dollars — what can I do?
COMMERCIAL INSURANCE · HIGH COPAY
The DUPIXENT MyWay® Copay Card almost certainly applies to your situation and may bring your cost to $0 — but you have to enroll in it proactively; it doesn’t apply automatically. Call 1-844-387-4936 (option 1) or visit dupixent.com to enroll. The program covers copay and coinsurance costs up to $13,000 per calendar year per patient. Once enrolled, you present the copay card at the specialty pharmacy when picking up your prescription, and it covers whatever your insurance doesn’t — up to the annual limit. There are three situations where the copay card does not work: (1) your plan has a “copay accumulator” or “copay maximizer” program that prevents manufacturer assistance from counting toward your deductible, (2) you’re on Medicare or Medicaid, or (3) you’re in certain states with restrictions on coupon programs. If your pharmacy tells you the card isn’t working, ask specifically whether your plan has a copay accumulator. If it does, call the patient assistance line — there may still be workarounds, and state laws in several jurisdictions have limited accumulator programs’ ability to block copay assistance. About 32% of commercially insured patients pay over $100 per month even with the copay card, usually because of accumulator programs or high-tier formulary placement.
📞 Enroll in copay card: 1-844-387-4936 (option 1)
🌐 Dupixent MyWay: dupixent.com
💡 Ask your pharmacy: does my plan have a copay accumulator?
⚠️ Card covers up to $13,000/year per patient
I have Medicare Part D — how do I manage the cost before I hit the $2,100 cap?
MEDICARE PART D · SENIORS
The new Medicare Prescription Payment Plan is the most practical tool for smoothing out the cash-flow challenge of the early-year deductible and cost-sharing before you hit the $2,100 annual cap. Here’s the reality of Medicare Part D and Dupixent: at list price, you’ll likely hit the $2,100 annual out-of-pocket cap within your first fill or two of the year. After that, Dupixent is covered at 100% for the rest of the calendar year. The challenge is that the initial out-of-pocket costs can be large and hit all at once in January when the new plan year starts. The Medicare Prescription Payment Plan (voluntary, administered by CMS) lets you spread your $2,100 annual maximum into roughly $175/month installments — same total cost, no interest, no fees, just an easier payment structure. Enroll through your Part D plan during open enrollment (October 15 – December 7) or when you first become eligible. If your income is at or below 150% of the federal poverty level (approximately $23,940 for a single person), apply for Extra Help through Social Security — it reduces your cost to about $3–$9 per fill regardless of the drug’s price. Apply at ssa.gov or call 1-800-772-1213. Remember: the manufacturer’s copay card cannot be used with Medicare. The PAP requires you to first apply for Extra Help, then use the denial letter (if denied) as documentation to qualify for free medication through the program.
💰 Cap: $2,100/year for all covered Part D drugs combined
📅 Payment plan: spread costs into ~$175/mo installments, no interest
🆘 Extra Help: SSA.gov or 1-800-772-1213 for low-income enrollees
⚠️ Copay card does NOT work with Medicare — use PAP instead
My insurance denied Dupixent — do I have to accept the denial?
INSURANCE DENIAL · APPEAL PROCESS
A denial is almost never the end. Most Dupixent denials are overturned on appeal — particularly when your prescriber requests a peer-to-peer review with the plan’s medical director. The most common denial reasons are: incomplete prior authorization documentation, unmet step therapy requirements (not yet documenting that you tried other therapies first), or formulary exclusion (Dupixent isn’t on your plan’s covered drug list). Here is the process that works most reliably. Step 1: Ask your doctor’s office to request a peer-to-peer review — a direct call between your physician and the insurance plan’s medical director. In these calls, your doctor presents your clinical case directly. Success rates are high when documentation is thorough. Step 2: If the peer-to-peer doesn’t resolve it, file a formal internal appeal. You have the right to appeal any denial. Your denial letter must state the reason and include instructions for appealing. Step 3: If the internal appeal fails, request an external or independent review. This process — free to patients in most states — brings in an independent reviewer unaffiliated with your insurer. About 50% of externally reviewed pharmacy denials are overturned. Step 4: If all appeals fail, apply for the DUPIXENT MyWay® PAP or discuss alternative therapies with your doctor while the process continues. The appeals process can take weeks to months — your doctor can sometimes request expedited review (72 hours) for urgent medical situations.
📞 Ask for peer-to-peer review: doctor calls insurance medical director
📝 File formal appeal: instructions in your denial letter
🏛️ External review: free, ~50% overturn rate in many states
⏰ Expedited review (72 hrs) available for urgent medical need
I have no insurance and I can’t afford Dupixent at list price — what are my options?
UNINSURED · NO COVERAGE · LOW INCOME
The DUPIXENT MyWay® Patient Assistance Program (PAP) can provide the medication at no cost to qualifying uninsured patients — but you have to apply, and your prescriber must participate. Eligibility is evaluated case by case, with income thresholds reported around 400% of the Federal Poverty Level (approximately $63,840 for a single-person household). If you earn above this threshold, you may still be evaluated — the program has discretion. To start: call 1-844-387-4936 (option 1). Your prescriber’s office must co-sign the enrollment form. If you’re in a gap before PAP approval comes through, ask your prescriber whether sample injections are available from their office supply — this can bridge one to two months of treatment while the paperwork processes. Beyond the manufacturer PAP, two additional programs are worth exploring: the Patient Advocate Foundation’s Co-Pay Relief Program at copayrelief.org provides financial assistance to patients with specific diagnoses, and NeedyMeds at needymeds.org maintains a database of disease-specific assistance programs by condition and state. Some states also have State Pharmaceutical Assistance Programs (SPAPs) that provide additional help. Your prescriber’s office should have a navigator or social worker familiar with these resources — if not, ask for a referral to one.
📞 Apply for free Dupixent: 1-844-387-4936 (option 1)
🌐 More help: needymeds.org and copayrelief.org
💊 Ask prescriber for samples while PAP processes
🏛️ State programs: check State Pharmaceutical Assistance Programs
I’m on Dupixent now and it’s working — how do I protect my access if my insurance changes?
EXISTING PATIENTS · COVERAGE CHANGES
A mid-year insurance change — losing a job, turning 65 and moving to Medicare, or a plan formulary update — is the most stressful situation for existing Dupixent patients because interrupting the medication can allow the condition to flare. Three things to do before any coverage change takes effect. First: contact DUPIXENT MyWay® at 1-844-387-4936 the moment you know your insurance is changing. They have experience bridging patients through coverage transitions and can sometimes provide emergency supply while new coverage is established. Second: if you’re transitioning to Medicare, know that the manufacturer’s copay card stops working the day your Medicare coverage begins. Set up your Part D plan’s prior authorization for Dupixent before your Medicare start date if possible — your prescriber can submit the PA in advance. Third: if you lose commercial coverage entirely, ask your prescriber to contact DUPIXENT MyWay® on your behalf to start the PAP process immediately. The program can sometimes provide an emergency bridge supply for patients with an established treatment history who have documented a sudden loss of coverage. Keep at least one spare box of injections on hand if your supply allows — this provides a buffer during any transition period.
📞 Coverage changing? Call immediately: 1-844-387-4936
⚠️ Copay card stops working on Medicare start date
📋 Submit Medicare PA before your coverage start date
🗓️ Keep one spare box — buffers any transition gap
📍 Find a Specialty Pharmacy or Help Near You
Dupixent must be filled at a specialty pharmacy — not at a standard retail location. Use the buttons below to find specialty pharmacies, local dermatology or allergy practices that prescribe Dupixent, or patient assistance resources near you.
🔑 Quick Reference — Every Number and Link You Need
📞 DUPIXENT MyWay®: 1-844-387-4936 (option 1) · Mon–Fri 8am–9pm ET
🌐 Cost and coverage tool: dupixent.com/support-savings/cost-insurance
💰 Medicare Extra Help: ssa.gov or 1-800-772-1213
🏥 Medicare Prescription Payment Plan: medicare.gov/mppp
🤝 NeedyMeds (assistance programs): needymeds.org
🩺 Patient Advocate Foundation Co-Pay Relief: copayrelief.org
🗺️ SHIP Medicare counseling (free): shiptacenter.org
📋 State Pharmaceutical Programs: find yours via needymeds.org/spap
📞 Appeal help (free): your state insurance commissioner
💊 Dupixent prescribing information: FDA.gov → dupilumab
✅ Step-by-Step — Find Your Actual Cost in Five Minutes
- Step 1: Identify your coverage type: commercial/employer insurance, Medicare Part D, Medicaid, or uninsured. Each has a completely different cost path — the steps below split based on this.
- Step 2 (Commercial insurance): Call DUPIXENT MyWay® at 1-844-387-4936 and enroll in the Copay Card. Present it at your specialty pharmacy when you fill — your cost may drop to $0. Ask your pharmacy if your plan has a copay accumulator program that could block this benefit.
- Step 3 (Medicare): Your copay card cannot be used. Check whether you qualify for Extra Help at SSA.gov. Enroll in the Medicare Prescription Payment Plan to spread your annual out-of-pocket costs into monthly installments. Most Part D patients reach the $2,100 annual cap after 1–2 fills — the rest of the year is free after that.
- Step 4 (Uninsured / can’t afford it): Call 1-844-387-4936 to apply for the Patient Assistance Program. Your prescriber must co-sign. Ask for samples from your doctor’s office to bridge the gap while approval processes. Check NeedyMeds and copayrelief.org for additional programs.
- Step 5 (Denied by insurance): Do not accept the first denial. Ask your doctor to request a peer-to-peer review. File the internal appeal. If denied again, request independent external review through your state insurance commissioner — it’s free and overturns about 50% of denials.
This guide covers Dupixent (dupilumab) pricing and financial assistance programs for informational purposes only. Drug prices, program eligibility, copay card terms, and Medicare out-of-pocket caps are subject to change. Prices shown reflect publicly reported U.S. figures and may not reflect your specific pharmacy, dose, insurance plan, or geographic location. This page has no affiliation with Regeneron, Sanofi, or any insurance company. Dupixent® and DUPIXENT MyWay® are registered trademarks of Sanofi and Regeneron Pharmaceuticals, Inc. Always consult your prescribing physician and pharmacist for treatment decisions and current program details. Medicare Extra Help eligibility and program details are set by the Social Security Administration and are subject to annual updates.